Earnings ·
Caris Life Sciences reports Q3 revenue of $275.4M and raises full-year guidance to $1.04-$1.05B
CAICaris Life Sciences, Inc.
Caris Life Sciences reported third-quarter 2026 total revenue of $275.4 million, a 27% increase from the prior year period, driven by strong growth in molecular profiling services and approximately 61,500 clinical cases completed. The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion, representing expected growth of 28% to 29%. Net income for the quarter was $15.3 million, or $0.05 per share, compared to $24.3 million in the prior year period. Adjusted EBITDA came in at $44.4 million. The company also highlighted operational milestones including the launch of Caris Assure Therapy Response Monitoring and enhanced sequencing capabilities. Caris Life Sciences is a TechBio company developing and commercializing precision medicine diagnostic solutions through molecular profiling, AI, and machine learning.